Human herpesvirus 6, 7 and 8 in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 128-137

  Le, J ^a   Gantt, S ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Exanthem subitum; ganciclovir; herpes virus; kaposis sarcoma; lymphoma; roseola infantum

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CIDOFOVIR; DOXORUBICIN; FOSCARNET; GANCICLOVIR; OKT 3; PACLITAXEL; PENCICLOVIR; RAPAMYCIN; RITUXIMAB; VALGANCICLOVIR; VIRUS DNA;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MYCOSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HERPESVIRIDAE INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874851001     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12106     Document Type: Article

References (163)

1. Pruksananonda P, Hall CB, Insel RA, et al. Primary human herpesvirus 6 infection in young children. N Engl J Med 1992; 326: 1445-1450.
2. Lee SO, Brown RA, Eid AJ, Razonable RR,. Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrol Dial Transplant 2011; 26: 2391-2393.
3. Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6: Questions and answers. Rev Med Virol 2012; 22: 144-155.
4. Clark DA, Nacheva EP, Leong HN, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: Implications for laboratory diagnosis. J Infect Dis 2006; 193: 912-916.
5. Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007; 79: 45-51.
6. Flamand L, Komaroff AL, Arbuckle JH, Medveczky PG, Ablashi DV,. Review, part 1: Human herpesvirus-6-basic biology, diagnostic testing, and antiviral efficacy. J Med Virol 2010; 82: 1560-1568.
7. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005; 352: 768-776.
8. Dewhurst S, McIntyre K, Schnabel K, Hall CB,. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. J Clin Microbiol 1993; 31: 416-418.
9. Razonable RR, Paya CV,. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8: 651-658.
10. Knox KK, Carrigan DR,. Active HHV-6 infection in the lymph nodes of HIV-infected patients: In vitro evidence that HHV-6 can break HIV latency. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 370-378.
11. Caserta MT, Hall CB, Schnabel K, Long CE, D'Heron N,. Primary human herpesvirus 7 infection: A comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr 1998; 133: 386-389.
12. Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (Exanthem subitum, Roseola infantum). Pediatrics 1994; 93: 104-108.
13. Suga S, Yoshikawa T, Nagai T, Asano Y,. Clinical features and virological findings in children with primary human herpesvirus 7 infection. Pediatrics 1997; 99: E4.
14. Wyatt LS, Frenkel N,. Human herpesvirus 7 is a constitutive inhabitant of adult human saliva. J Virol 1992; 66: 3206-3209.
15. Di Luca D, Mirandola P, Ravaioli T, et al. Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. J Med Virol 1995; 45: 462-468.
16. Pereira CM, Gasparetto PF, Corrêa ME, Costa FF, de Almeida OP, Barjas-Castro ML,. Human herpesvirus 6 in oral fluids from healthy individuals. Arch Oral Biol 2004; 49: 1043-1046.
17. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331: 432-438.
18. Dahl H, Fjaertoft G, Norsted T, Wang FZ, Mousavi-Jazi M, Linde A,. Reactivation of human herpesvirus 6 during pregnancy. J Infect Dis 1999; 180: 2035-2038.
19. Wyatt LS, Rodriguez WJ, Balachandran N, Frenkel N,. Human herpesvirus 7: Antigenic properties and prevalence in children and adults. J Virol 1991; 65: 6260-6265.
20. Clark DA, Freeland ML, Mackie LK, Jarrett RF, Onions DE,. Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis 1993; 168: 251-252.
21. Akashi K, Eizuru Y, Sumiyoshi Y, et al. Brief report: severe infectious mononucleosis-like syndrome and primary human herpesvirus 6 infection in an adult. N Engl J Med 1993; 329: 168-171.
22. Niederman JC, Liu CR, Kaplan MH, Brown NA,. Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet 1988; 2 (8615): 817-819.
23. Rossi C, Delforge ML, Jacobs F, et al. Fatal primary infection due to human herpesvirus 6 variant A in a renal transplant recipient. Transplantation 2001; 71: 288-292.
24. Feldstein AE, Razonable RR, Boyce TG, et al. Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients. Pediatr Transplant 2003; 7: 125-129.
25. Yoshikawa T, Ihira M, Suzuki K, et al. Human herpesvirus 6 infection after living related liver transplantation. J Med Virol 2000; 62: 52-59.
26. Ratnamohan VM, Chapman J, Howse H, et al. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 1998; 66: 877-882.
27. Cervera C, Marcos MA, Linares L, et al. A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients. Transplantation 2006; 82: 979-982.
28. Yoshikawa T, Suga S, Asano Y, et al. A prospective study of human herpesvirus-6 infection in renal transplantation. Transplantation 1992; 54: 879-883.
29. Singh N, Carrigan DR,. Human herpesvirus-6 in transplantation: An emerging pathogen. Ann Intern Med 1996; 124: 1065-1071.
30. De, Bolle L, Naesens L, De Clercq E,. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18: 217-245.
31. Lautenschlager I, Razonable RR,. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: Review. Transpl Int 2012; 25: 493-502.
32. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73: 599-604.
33. Lautenschlager I, Linnavuori K, Höckerstedt K,. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000; 69: 2561-2566.
34. Singh N, Carrigan DR, Gayowski T, Singh J, Marino IR,. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995; 60: 1355-1357.
35. Potenza L, Luppi M, Barozzi P, et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 2008; 359: 593-602.
36. Randhawa PS, Jenkins FJ, Nalesnik MA, et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997; 21: 847-853.
37. Halme L, Arola J, Höckerstedt K, Lautenschlager I,. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008; 46: 434-439.
38. Delbridge MS, Karim MS, Shrestha BM, McKane W,. Colitis in a renal transplant patient with human herpesvirus-6 infection. Transpl Infect Dis 2006; 8: 226-228.
39. Lamoth F, Jayet PY, Aubert JD, et al. Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol 2008; 80: 1804-1807.
40. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I,. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007; 26: 41-47.
41. Costa C, Curtoni A, Bergallo M, et al. Quantitative detection of HHV-6 and HHV-7 in transbronchial biopsies from lung transplant recipients. New Microbiol 2011; 34: 275-280.
42. Nash PJ, Avery RK, Tang WH, Starling RC, Taege AJ, Yamani MH,. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4: 1200-1203.
43. Singh N, Carrigan DR, Gayowski T, Marino IR,. Human herpesvirus-6 infection in liver transplant recipients: Documentation of pathogenicity. Transplantation 1997; 64: 674-678.
44. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17: 114-120.
45. Harma M, Hockerstedt K, Krogerus L, Lautenschlager I,. Pretransplant human herpesvirus 6 infection of patients with acute liver failure is a risk factor for posttransplant human herpesvirus 6 infection of the liver. Transplantation 2006; 81: 367-372.
46. Pilmore H, Collins J, Dittmer I, et al. Fatal human herpesvirus-6 infection after renal transplantation. Transplantation 2009; 88: 762-765.
47. Lee SO, Brown RA, Razonable RR,. Chromosomally integrated human herpesvirus-6 in transplant recipients. Transpl Infect Dis 2012; 14: 346-354.
48. Moschettini D, De Milito A, Catucci M, et al. Detection of human herpesviruses 6 and 7 in heart transplant recipients by a multiplex polymerase chain reaction method. Eur J Clin Microbiol Infect Dis 1998; 17: 117-119.
49. Pascher A, Klupp J, Schulz RJ, Dignass A, Neuhaus P,. CMV, EBV, HHV6, and HHV7 infections after intestinal transplantation without specific antiviral prophylaxis. Transplant Proc 2004; 36: 381-382.
50. Antón A, Cervera C, Pumarola T, et al. Human herpesvirus 7 primary infection in kidney transplant recipients. Transplantation 2008; 85: 298-302.
51. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59: 496-501.
52. Thomasini RL, Sampaio AM, Bonon SH, et al. Detection and monitoring of human herpesvirus 7 in adult liver transplant patients: Impact on clinical course and association with cytomegalovirus. Transplant Proc 2007; 39: 1537-1539.
53. Dockrell DH, Prada J, Jones MF, et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997; 176: 1135-1140.
54. Mendez JC, Dockrell DH, Espy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179-184.
55. Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS,. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000; 70: 213-216.
56. Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000; 69: 2400-2404.
57. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178: 1783-1786.
58. Härmä M, Höckerstedt K, Lyytikäinen O, Lautenschlager I,. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78: 800-805.
59. Lautenschlager I, Lappalainen M, Linnavuori K, Suni J, Höckerstedt K,. CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. J Clin Virol 2002; 25 Suppl 2: S57-S61.
60. Guardia AC, Stucchi RS, Sampaio AM, et al. Human herpesvirus 6 in donor biopsies associated with the incidence of clinical cytomegalovirus disease and hepatitis C virus recurrence. Int J Infect Dis 2012; 16: e124-e129.
61. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67: 399-403.
62. Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69: 2566-2573.
63. Jacobs F, Knoop C, Brancart F, et al. Human herpesvirus-6 infection after lung and heart-lung transplantation: A prospective longitudinal study. Transplantation 2003; 75: 1996-2001.
64. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16: 92-96.
65. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466.
66. Ohashi M, Sugata K, Ihira M, et al. Human herpesvirus 6 infection in adult living related liver transplant recipients. Liver Transpl 2008; 14: 100-109.
67. Lautenschlager I, Hockerstedt K, Linnavuori K, Taskinen E,. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998; 26: 702-707.
68. Chapenko S, Folkmane I, Ziedina I, et al. Association of HHV-6 and HHV-7 reactivation with the development of chronic allograft nephropathy. J Clin Virol 2009; 46: 29-32.
69. Astegiano S, Costa C, Terlizzi ME, et al. Detection of human herpesvirus-7 DNA in bronchoalveolar lavage. Intervirology 2010; 53: 119-123.
70. Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: A risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5: 2982-2991.
71. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87: 719-725.
72. Lee SO, Brown RA, Razonable RR,. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation 2011; 92: 224-229.
73. Lanphear BP, Hall CB, Black J, Auinger P,. Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. Pediatr Infect Dis J 1998; 17: 792-795.
74. Okuno T, Higashi K, Shiraki K, et al. Human herpesvirus 6 infection in renal transplantation. Transplantation 1990; 49: 519-522.
75. Singh N, Bentlejewski C, Carrigan DR, Gayowski T, Knox KK, Zeevi A,. Persistent lack of human herpesvirus-6 specific T-helper cell response in liver transplant recipients. Transpl Infect Dis 2002; 4: 59-63.
76. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.
77. Sampaio AM, Thomasini RL, Guardia AC, et al. Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in adult liver transplant recipients: Diagnosis based on antigenemia. Transplant Proc 2011; 43: 1357-1359.
78. Flamand L, Gravel A, Boutolleau D, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum. J Clin Microbiol 2008; 46: 2700-2706.
79. Norton RA, Caserta MT, Hall CB, Schnabel K, Hocknell P, Dewhurst S,. Detection of human herpesvirus 6 by reverse transcription-PCR. J Clin Microbiol 1999; 37: 3672-3675.
80. Blumberg BM, Mock DJ, Powers JM, et al. The HHV6 paradox: Ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol 2000; 16: 159-178.
81. Deback C, Agbalika F, Scieux C, et al. Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit. J Virol Methods 2008; 149: 285-291.
82. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A,. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 2008; 80: 467-477.
83. Locatelli G, Santoro F, Veglia F, Gobbi A, Lusso P, Malnati MS,. Real-time quantitative PCR for human herpesvirus 6 DNA. J Clin Microbiol 2000; 38: 4042-4048.
84. Boutolleau D, Duros C, Bonnafous P, et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol 2006; 35: 257-263.
85. Safronetz D, Humar A, Tipples GA,. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods 2003; 112 (1-2): 99-105.
86. Achour A, Boutolleau D, Slim A, Agut H, Gautheret-Dejean A,. Human herpesvirus-6 (HHV-6) DNA in plasma reflects the presence of infected blood cells rather than circulating viral particles. J Clin Virol 2007; 38: 280-285.
87. Caserta MT, Hall CB, Schnabel K, et al. Diagnostic assays for active infection with human herpesvirus 6 (HHV-6). J Clin Virol 2010; 48: 55-57.
88. Pradeau K, Bordessoule D, Szelag JC, et al. A reverse transcription-nested PCR assay for HHV-6 mRNA early transcript detection after transplantation. J Virol Methods 2006; 134 (1-2): 41-47.
89. Hoshino K, Nishi T, Adachi H, et al. Human herpesvirus-6 infection in renal allografts: Retrospective immunohistochemical study in Japanese recipients. Transpl Int 1995; 8: 169-173.
90. Lautenschlager I, Höckerstedt K, Linnavuori K, Taskinen E,. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998; 26: 702-707.
91. Helanterä I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH,. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339-371.
92. Lempinen M, Halme L, Arola J, Honkanen E, Salmela K, Lautenschlager I,. HHV-6B is frequently found in the gastrointestinal tract in kidney transplantation patients. Transpl Int 2012; 25: 776-782.
93. Agut H., Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol 2011; 52: 164-171.
94. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus co-infections in patients with CMV disease: Correlation with clinical and virologic outcomes. Am J Transplant 2009; 9: 374-381.
95. Yoshida M, Yamada M, Tsukazaki T, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998; 40 (1-2): 73-84.
96. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J,. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11: 381-395.
97. Ljungman P, Singh N,. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006; 37 Suppl 1: S87-S91.
98. Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001; 82 (Pt 11): 2767-2776.
99. Isegawa Y, Hara J, Amo K, et al. Human herpesvirus 6 ganciclovir- resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009; 44: 15-19.
100. Bonnafous P, Boutolleau D, Naesens L, Deback C, Gautheret-Dejean A, Agut H,. Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Res 2008; 77: 237-240.
101. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV,. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192: 1331-1339.
102. Galarraga MC, Gomez E, de Ona M, et al. Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Transplant Proc 2005; 37: 2124-2126.
103. Lebbe C, Legendre C, Frances C,. Kaposi sarcoma in transplantation. Transplant Rev (Orlando) 2008; 22: 252-261.
104. Mesri EA, Cesarman E, Boshoff C,. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707-719.
105. Ariza-Heredia EJ, Razonable RR,. Human herpes virus 8 in solid organ transplantation. Transplantation 2011; 92: 837-844.
106. Pietrosi G, Vizzini G, Pipitone L, et al. Primary and reactivated HHV8 infection and disease after liver transplantation: A prospective study. Am J Transplant 2011; 11: 2715-2723.
107. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343: 1378-1385.
108. Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002; 74: 131-132.
109. Regamey N, Hess V, Passweg J, et al. Infection with human herpesvirus 8 and transplant-associated gammopathy. Transplantation 2004; 77: 1551-1554.
110. Ganem D., KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J Clin Invest; 120: 939-949.
111. Uldrick TS, Whitby D,. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett; 305: 150-162.
112. Nguyen HQ, Casper C,. The epidemiology of Kaposi sarcoma. In:, Pantanowitz JL, Stebbing J, Dezube B, eds. Kaposi Sarcoma: A Model of Oncogenesis. Kerala, India: Research Signpost, 2010: 197-232.
113. Blauvelt A, Sei S, Cook PM, Schulz TF, Jeang KT,. Human herpesvirus 8 infection occurs following adolescence in the United States. J Infect Dis 1997; 176: 771-774.
114. Mayama S, Cuevas LE, Sheldon J, et al. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer 1998; 77: 817-820.
115. Farge D, Lebbe C, Marjanovic Z, et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation 1999; 67: 1236-1242.
116. Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39: 506-508.
117. Ahmadpoor P, Ilkhanizadeh B, Sharifzadeh P, et al. Seroprevalence of human herpes virus-8 in renal transplant recipients: A single center study from Iran. Transplant Proc 2007; 39: 1000-1002.
118. Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: The most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225-232.
119. Farge D., Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993; 2: 339-343.
120. Piselli P, Busnach G, Citterio F, et al. Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970-2006. Transplant Proc 2009; 41: 1227-1230.
121. Hwang JK, Moon IS, Kim JI,. Malignancies after kidney transplantation: A 40-year single-center experience in Korea. Transpl Int 2011; 24: 716-721.
122. Andreoni M, Goletti D, Pezzotti P, et al. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. J Infect 2001; 43: 195-199.
123. Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: A multicenter study. Eur J Dermatol 2006; 16: 553-557.
124. Mbulaiteye SM, Engels EA,. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119: 2685-2691.
125. Antman K, Chang Y,. Kaposi's sarcoma. N Engl J Med 2000; 342: 1027-1038.
126. Moosa MR., Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore) 2005; 84: 12-22.
127. Garcia-Astudillo LA, Leyva-Cobian F,. Human herpesvirus-8 infection and Kaposi's sarcoma after liver and kidney transplantation in different geographical areas of Spain. Transpl Immunol 2006; 17: 65-69.
128. Frances C, Mouquet C, Marcelin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 2000; 69: 1776-1779.
129. Marcelin AG, Roque-Afonso AM, Hurtova M, et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 2004; 10: 295-300.
130. Di Benedetto F, Di Sandro S, De Ruvo N, et al. Kaposi's sarcoma after liver transplantation. J Cancer Res Clin Oncol 2008; 134: 653-658.
131. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358-1363.
132. Frances C, Marcelin AG, Legendre C, et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant 2009; 9: 2580-2586.
133. Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9: 554-561.
134. Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN,. Sirolimus for Kaposi's sarcoma. J Heart Lung Transplant 2006; 25: 726-729.
135. Gantt S, Casper C,. Human herpesvirus 8-associated neoplasms: The roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24: 295-301.
136. Barozzi P, Bonini C, Potenza L, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008; 86: 738-744.
137. Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002; 32: 2711-2720.
138. Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J,. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004; 189: 2016-2022.
139. Dialyna IA, Graham D, Rezaee R, et al. Anti-HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. Aids 2004; 18: 1263-1270.
140. Pantanowitz L, Fruh K, Marconi S, Moses AV, Dezube BJ,. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol 2008; 8: 7.
141. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
142. Spira TJ, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol 2000; 38: 2174-2180.
143. Laney AS, Peters JS, Manzi SM, Kingsley LA, Chang Y, Moore PS,. Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J Clin Microbiol 2006; 44: 3734-3741.
144. Mendez JC, Procop GW, Espy MJ, Smith TF, McGregor CG, Paya CV,. Relationship of HHV8 replication and Kaposi's sarcoma after solid organ transplantation. Transplantation 1999; 67: 1200-1201.
145. Pozo F, Tenorio A, de la, Mata M, de Ory F, Torre-Cisneros J,. Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation 2000; 70: 395-397.
146. Pellet C, Chevret S, Frances C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002; 186: 110-113.
147. Dudderidge TJ, Khalifa M, Jeffery R, Amlot P, Al-Akraa M, Sweny P,. Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureter. Transpl Infect Dis 2008; 10: 221-226.
148. D'Amico F, Fuxman C, Nachman F, et al. Visceral Kaposi's sarcoma remission after intestinal transplant. First case report and systematic literature review. Transplantation 2010; 90: 547-554.
149. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C,. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: Report of 13 cases. Am J Nephrol 1994; 14: 121-126.
150. Duman S, Toz H, Asci G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17: 892-896.
151. van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010; 340: c570.
152. Kolhe N, Mamode N, Van der Walt J, Pattison J,. Regression of post-transplant Kaposi's sarcoma using sirolimus. Int J Clin Pract 2006; 60: 1509-1512.
153. Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F,. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008; 8: 707-710.
154. Nichols LA, Adang LA, Kedes DH,. Rapamycin blocks production of KSHV/HHV8: Insights into the anti-tumor activity of an immunosuppressant drug. PLoS One 2011; 6: e14535.
155. Sullivan RJ, Pantanowitz L, Dezube BJ,. Targeted therapy for Kaposi sarcoma. BioDrugs 2009; 23: 69-75.
156. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol 1997; 15: 2371-2377.
157. Dittmer DP, Richards KL, Damania B,. Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers. Front Microbiol 2012; 3: 141.
158. Reddy D, Mitsuyasu R,. HIV-associated multicentric Castleman disease. Curr Opin Oncol 2011; 23: 475-481.
159. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA,. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340: 1063-1070.
160. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198: 23-30.
161. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD,. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889.
162. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589.
163. Babel N, Eibl N, Ulrich C, et al. Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 2008; 10: 59-62.